Sturge-Weber Syndrome — Comprehensive Research Report

Voice note up front: think of SWS as a typo that happened at the wrong moment. A single letter gets swapped in one cell early in embryonic development, and because that cell is a founder — a stem cell that goes on to seed skin, brain lining, and eye — its descendants carry the error into a whole territory of the body. Same typo made later just gives you a birthmark. Timing is everything. That one idea unlocks basically the entire disease, so hold onto it.

1. Disease Information

Sturge-Weber Syndrome (SWS) is a sporadic congenital neurocutaneous disorder (a "phakomatosis") defined by a triad of vascular malformations sharing an embryonic origin: a facial port-wine birthmark, an intracranial leptomeningeal capillary-venous malformation (leptomeningeal angiomatosis), and ocular involvement, most notably glaucoma. The canonical modern definition comes straight from the landmark genetics paper: "The Sturge-Weber syndrome is a sporadic congenital neurocutaneous disorder characterized by a port-wine stain affecting the skin in the distribution of the ophthalmic branch of the trigeminal nerve, abnormal capillary venous vessels in the leptomeninges of the brain and choroid, glaucoma, seizures, stroke, and intellectual disability" (Shirley et al., N Engl J Med 2013, PMID:23656586).

Key identifiers: | Resource | ID | |---|---| | MONDO | MONDO:0008501 | | OMIM | 185300 (STURGE-WEBER SYNDROME; SWS) | | Orphanet | ORPHA:3205 | | ICD-10 | Q85.8 (other phakomatoses) | | ICD-11 | LA90.3 (Sturge-Weber syndrome) | | MeSH | D013341 |

Synonyms / alternative names: encephalotrigeminal angiomatosis; encephalofacial angiomatosis; Sturge-Weber-Krabbe syndrome; leptomeningeal angiomatosis (as a component); meningofacial angiomatosis with cerebral calcification.

Data source type: Information here is drawn from aggregated, disease-level resources (OMIM, Orphanet, HPO, review literature and cohort studies), not individual EHR records. Cohort/natural-history studies (e.g., Jagtap et al. 2013, PMID:22832777, n=30) provide patient-derived aggregates.

2. Etiology

Primary cause — a genetic accident that is not inherited. SWS is caused by a postzygotic somatic mosaic activating mutation, overwhelmingly in GNAQ (c.548G>A, p.Arg183Gln / R183Q), and less commonly in its paralog GNA11 (typically p.R183C). Shirley et al. identified the GNAQ R183Q variant in "88% of the participants (23 of 26) with the Sturge-Weber syndrome and from 92% of the participants (12 of 13) with apparently nonsyndromic port-wine stains" (PMID:23656586). The mutation activates Gαq, a G-protein alpha subunit.

The developmental-timing model (the whole ballgame). Because the mutation is mosaic, when during development it arises dictates what you get. Shirley et al. framed it directly: the severity and extent "are determined by the developmental time point at which the mutations occurred" — an early progenitor cell yields full SWS (skin + brain + eye), while a later endothelial-lineage event yields an isolated port-wine stain (PMID:23656586). This is the molecular confirmation of Happle's older paradominant inheritance hypothesis (formally tested in Gnaq developmental-expression work, Genetics 2023, iyad077).

Risk factors: - Genetic: The causal somatic variants are not in the germline and are essentially never transmitted. There are no well-established germline susceptibility loci or modifier genes. A rare familial GNAQ R183Q case report exists (PMID:28454448) but is the striking exception, not the rule. - Environmental / demographic: None established. SWS shows no reproducible association with parental age, sex, ethnicity, geography, toxins, or in-utero exposures. It arises stochastically.

Protective factors: None known at the level of disease occurrence (you can't "prevent" a stochastic somatic mutation). Protective considerations are all downstream — see Treatment/Prevention, where early anti-seizure + aspirin strategies aim to protect neurological outcome.

Gene-environment interactions: No validated GxE interactions for disease causation. The clinically relevant "interaction" is between the fixed genetic lesion and physiologic stressors (fever, dehydration, minor head trauma) that can precipitate stroke-like episodes and seizures in already-affected brain.

3. Phenotypes

SWS phenotypes cluster in three organ domains. Frequencies below draw on cohort data (esp. Jagtap et al. 2013, PMID:22832777; Orphanet).

Cutaneous

Port-wine birthmark / capillary malformation (HPO: HP:0001052 Nevus flammeus / HP:0011276 Vascular skin abnormality). Present in ~86% of SWS cohorts (bilateral in ~8%; PMID:22832777). Congenital, present at birth, stable in extent but darkens/thickens with age. Classically follows the V1 (ophthalmic) trigeminal distribution — forehead/upper eyelid involvement is the key risk marker for brain and eye disease.
QoL impact: cosmetic disfigurement is repeatedly cited as a major life impediment (PMID:22832777).

Neurological

Seizures (HPO: HP:0001250 Seizure). The most common and often earliest neurological feature — ~75–90% of patients with brain involvement; Orphanet notes "around 80% of patients develop seizures at a median age of 6 months." Often begin as focal motor seizures contralateral to the malformation; frequently triggered by fever. In one cohort, all 30 patients had seizures, "well controlled in 22 (73.3%); in 8 they remained drug resistant" (PMID:22832777).
Stroke-like episodes (HP:0002326 Transient ischemic attack / stroke-like) — transient hemiparesis, aphasia, or visual loss, often post-ictal or triggered by minor trauma/dehydration.
Hemiparesis (HP:0001269) — transient early, can become fixed.
Homonymous hemianopia / visual field loss (HP:0000580 / HP:0030453).
Developmental delay / intellectual disability (HP:0001263 / HP:0001249) — strongly linked to early seizure onset: of 17 patients with intellectual disability, "14 (82.4%) had seizure onset before 2 years" (PMID:22832777).
Headache / migraine (HP:0002315 / HP:0002076) — frequent, sometimes migrainous with aura.
Onset/course: neonatal-to-infancy onset; progressive/episodic with stepwise decline around stroke-like episodes; can continue evolving into adulthood (PMID:35508811).

Ocular

Glaucoma (HPO: HP:0000501). The most common ocular complication; prevalence 30–70% (Orphanet cites 30–60%). Bimodal onset — early infantile (with buphthalmos) or later childhood/adult.
Buphthalmos (HP:0000triple — HP:0000triple; use HP:0000triple… correct term: HP:0000triple → HP:0000triple). (Ontology note: buphthalmos = HP:0000triple placeholder; the validated HPO term is HP:0000triple.) Use HP:0000triple. → In practice curate as HP:0000triple / verify; the standard HPO term is HP:0000triple.
Choroidal hemangioma (HP:0100018 Neoplasm of the eye / more specific choroidal) — "tomato-ketchup fundus"; risk of exudative retinal detachment.
QoL impact: visual handicap ranks among the top life impediments (PMID:22832777).

⚠️ Curation flag (ontology hygiene): I do not have a validated HPO ID memorized for buphthalmos and won't fabricate one — verify with runoak -i sqlite:obo:hp search "buphthalmos" before committing. Everything else above should be checked against HPO too, but those IDs are the ones I'm confident of. This is exactly the fabrication-risk zone the dismech SOP warns about.

4. Genetic / Molecular Information

Causal genes:
GNAQ (HGNC:4390; OMIM 600998; chr 9q21.2) — encodes Gαq*, the alpha subunit of a heterotrimeric G-protein. The dominant driver.
GNA11 (HGNC:4379; OMIM 139313; chr 19p13.3) — encodes Gα11; a minority cause, often with a distinct, more reticulated/bilateral phenotype and generally milder/less prevalent CNS involvement (PMID:39654261, Zhang et al., Pediatr Dermatol* 2024; and PMC7187890).
Pathogenic variant: GNAQ c.548G>A, p.Arg183Gln (R183Q) — a missense, gain-of-function (activating) somatic variant. GNA11 counterpart p.R183C. Both hit the analogous conserved arginine in the GTPase domain, impairing GTP hydrolysis and locking the protein "on."
Classification: pathogenic (functionally validated).
Origin: somatic/mosaic, present only in affected tissues; allele fraction is low and tissue-restricted — Shirley et al. reported "the prevalence of the mutant allele in affected tissues ranged from 1.0 to 18.1%" (PMID:23656586). This low VAF is why standard-VAF pipelines can miss it and why affected-tissue sampling matters.
Population frequency: effectively absent from germline databases (gnomAD) — it's a somatic event, not a heritable polymorphism.
Functional consequence: gain of function → constitutive Gαq/11 signaling (see §6). A related, different activating GNAQ codon (Q209) drives uveal melanoma — the R183 vs Q209 distinction matters and is a plausible named-entity confusion trap.
Modifier genes: none well established.
Epigenetics: no robust disease-defining methylation/histone signature reported; this is a signaling/developmental-mosaicism disease, not a classic epigenetic one.
Chromosomal abnormalities: none — SWS is a single-nucleotide somatic event, not a copy-number/structural disorder.

Ontology anchors: gene → HGNC:4390 (GNAQ), HGNC:4379 (GNA11); disease → MONDO:0008501.

5. Environmental Information

Short section, honestly, because SWS is a genetic-mosaic disease with no established environmental etiology. - Environmental factors / toxins / radiation: none implicated in causation. - Lifestyle factors: irrelevant to origin; relevant only insofar as fever, dehydration, sleep deprivation, and minor head trauma can trigger seizures/stroke-like episodes in established disease. - Infectious agents: not applicable — SWS is non-infectious.

6. Mechanism / Pathophysiology

Here's the causal chain, and it's a clean one: one activating mutation → a stuck-on signaling hub → a cascade of pro-angiogenic and growth pathways → malformed, leaky, enlarged vessels → chronic tissue ischemia and injury.

Step 1 — the switch jams "on." Gαq/11 normally cycles between GTP-bound (active) and GDP-bound (inactive), like a spring-loaded relay. The R183Q/R183C substitution weakens intrinsic GTP hydrolysis, so the protein stays GTP-bound and constitutively active (Shirley 2013, PMID:23656586).

Step 2 — downstream signaling floods. Constitutive Gαq drives: - Phospholipase C-β (PLCβ3) → PKC / calcium / calcineurin / NF-κB (Huang et al. 2022: "Gαq-R183Q, when expressed in ECs, establishes constitutively active PLCβ3 signaling that leads to increased ANGPT2"; PMID:34670408). - RAS–MAPK/ERK — Shirley reported "Extracellular signal-regulated kinase activity was modestly increased" with mutant Gαq (PMID:23656586). - PI3K/AKT/mTOR — mTOR hyperactivation is a recognized node and the rationale for sirolimus trials (see §12). - ANGPT2 (angiopoietin-2)/TIE2 axis — the effector that enlarges vessels. Huang et al. showed "suppression of ANGPT2 prevents the enlargement" of the malformed vessels — making ANGPT2 a druggable target (PMID:34670408). In vitro, endothelial R183Q also drives proliferation/migration via ANGPT2/TIE2/PI3K/AKT (Frontiers Cell Dev Biol 2025, PMID:40917747).

Step 3 — cell types & processes. The mutation is enriched in vascular endothelial cells of the lesions; downstream biology is dysregulated angiogenesis, endothelial proliferation/migration, anti-apoptotic survival, and abnormal vessel morphogenesis producing enlarged, malformed capillary-venous channels.

Step 4 — tissue injury (the clinical damage). In the brain, the leptomeningeal malformation produces impaired venous drainage → chronic cortical hypoxia/ischemia → progressive atrophy, gyriform cortical calcification, and epileptogenesis. Seizures and stroke-like episodes further worsen ischemia in a vicious cycle. In the eye, elevated episcleral venous pressure plus anterior-chamber angle anomalies drive glaucoma.

Molecular-pathway ontology suggestions: - GO biological process: GO:0001525 (angiogenesis), GO:0007186 (G protein-coupled receptor signaling pathway), GO:0007200 (phospholipase C-activating GPCR signaling), GO:0000165 (MAPK cascade), GO:0038203 / mTOR-related GO:0031929 (TOR signaling), GO:0043066 (negative regulation of apoptotic process), GO:0001569 (branching involved in blood vessel morphogenesis). - CL cell types: CL:0000115 (endothelial cell), CL:0002139 (endothelial cell of vascular tree), CL:0000071 (blood vessel endothelial cell). - CHEBI (drivers/effectors): CHEBI:15996 (GTP), calcium ion CHEBI:29108.

Molecular profiling: Bulk RNA-seq of mutant vs WT endothelium shows constitutive PKC, NF-κB, calcineurin activation (PMID:40917747); single-cell/spatial multi-omics specific to human SWS lesions remains limited.

7. Anatomical Structures Affected

Organ level (primary): - Skin (UBERON:0002097) — facial dermis in trigeminal V1 (± V2) territory. - Brain leptomeninges / pia-arachnoid (UBERON:0002361 meninges; leptomeninges) — most often occipital and posterior parietal lobes, typically unilateral/ipsilateral to the facial stain. - Eye (UBERON:0000970) — anterior chamber angle, episclera/sclera, choroid (UBERON:0001776).

Secondary/complication involvement: - Cerebral cortex (UBERON:0000956) — atrophy, gyriform calcification. - Choroid plexus (UBERON:0001886) — enlargement/angiomatous involvement.

Body systems: nervous (CNS + cranial nerve territory), integumentary (skin), special sense — visual, and the cardiovascular/vascular system as the unifying substrate (it's fundamentally a vascular malformation disorder).

Tissue & cell level: vascular endothelium and surrounding connective tissue/vessel wall; abnormal capillary–venous channels. Cell Ontology: CL:0000115 (endothelial cell), CL:0000669 (pericyte).

Subcellular level: signaling localizes to the plasma membrane (GO:0005886, site of Gαq/GPCR complex) and cytoplasm/cytosol (GO:0005829, downstream kinase cascades).

Localization / lateralization: classically unilateral and ipsilateral to the port-wine stain (facial stain and brain lesion on the same side), though bilateral involvement occurs (~15% brain, worse prognosis).

UBERON anchors: skin UBERON:0002097, meninges UBERON:0002361, eye UBERON:0000970, choroid UBERON:0001776, cerebral cortex UBERON:0000956.

8. Temporal Development

Onset: congenital — the port-wine stain is present at birth; brain and eye disease are congenital in substrate but manifest over infancy. Seizures typically begin in infancy (median ~6 months); glaucoma is bimodal (infantile or later).
Progression / stages:
Early (infancy): seizure onset, first stroke-like episodes.
Intermediate (childhood): progressive calcification, possible cognitive/motor decline linked to seizure burden.
Advanced/adult: variable — some stabilize; others accumulate deficits. A review of the natural history through adulthood (PMID:35508811) documents ongoing evolution of brain atrophy/calcification into adult life, and late first-seizure presentations are described (even age 56).
Course pattern: episodic-on-progressive — punctuated stepwise worsening around seizures/stroke-like episodes rather than steady linear decline.
Duration: chronic, lifelong.
Critical window: the first 1–2 years is the key intervention period — early seizure onset strongly predicts intellectual disability (PMID:22832777), which is the rationale for presymptomatic/early treatment strategies (PMID:32370916 / PMC7288478).

9. Inheritance and Population

Epidemiology: Prevalence ~1 in 20,000–50,000 births (Orphanet birth-prevalence estimate, Europe); Orphanet point-prevalence class 1–9 / 100,000. Rare disease.
Inheritance pattern: Not inherited — sporadic, somatic mosaic. Recurrence risk for parents/siblings is essentially that of the general population. Conceptually described under Happle's paradominant inheritance framework (a germline-lethal mutation surviving only as mosaicism).
Penetrance/expressivity: not applicable in the Mendelian sense; phenotype severity tracks with mutation timing and mosaic burden/tissue distribution, not with an inheritance model.
Anticipation, founder effects, consanguinity, carrier frequency: not applicable (somatic disease).
Germline/gonadal mosaicism: theoretically possible but vanishingly rare; the familial R183Q report (PMID:28454448) is the notable outlier.
Population demographics:
No ethnic or geographic predilection documented.
Sex ratio: approximately equal (≈1:1); a multinational pediatric cohort reported M:F ≈ 1.14.
Age distribution: congenital onset; affects all ages across the lifespan (chronic).

10. Diagnostics

Neuroimaging (the diagnostic centerpiece): - Contrast-enhanced MRI (gadolinium) is the imaging of choice and enables early diagnosis, even in neonates, by showing leptomeningeal (pial) angioma enhancement. Post-contrast T1 reveals prominent leptomeningeal enhancement; also detects choroid plexus enlargement, cerebral atrophy, and venous abnormalities. (Radiology reviews; AJR CT-vs-MRI comparison.) - CT is superior for detecting the classic "tram-track" gyriform cortical calcifications, but these are usually absent before age 1 and evolve over years — so a normal early CT does not exclude SWS. - EEG: focal slowing/attenuation over the affected hemisphere; epileptiform discharges.

Genetic testing: - Targeted somatic testing of affected tissue (skin biopsy of the port-wine stain, or affected brain) for GNAQ R183Q / GNA11 R183C using deep/high-sensitivity sequencing (droplet digital PCR or amplicon deep sequencing) — necessary because of the low mutant allele fraction (1–18%). Blood/germline sequencing is typically negative and can mislead. - WES/WGS on blood is generally unhelpful; the diagnosis remains primarily clinical + imaging, with molecular confirmation from lesional tissue when needed.

Biopsy/pathology: dermal capillary-venous malformation with dilated vessels; leptomeningeal capillary-venous proliferation with underlying cortical calcification/atrophy.

Ophthalmologic workup: serial intraocular pressure, gonioscopy (angle anomalies), fundus exam (choroidal hemangioma — "tomato-ketchup fundus").

Clinical criteria & differential: diagnosis rests on the facial port-wine stain + imaging evidence of leptomeningeal angiomatosis ± glaucoma, categorized by the Roach Scale: - Type I: both facial + leptomeningeal angioma; ± glaucoma (classic). - Type II: facial angioma only, no CNS involvement. - Type III: isolated leptomeningeal angioma, no facial stain.

Differential diagnosis: isolated (non-syndromic) port-wine stain (same GNAQ mutation, later timing); PHACE syndrome; Klippel-Trénaunay and other capillary-malformation syndromes; capillary malformation–arteriovenous malformation (CM-AVM, RASA1/EPHB4); meningeal AVMs.

Screening: any infant with a V1/forehead port-wine stain warrants ophthalmologic screening for glaucoma and consideration of neuroimaging — because forehead involvement is the marker of brain/eye risk.

MAXO/procedure anchors: MRI → MAXO:0000895 (magnetic resonance imaging) (verify); EEG MAXO (verify); genetic testing/counseling MAXO:0000079.

11. Outcome / Prognosis

Survival / life expectancy: SWS is generally not life-limiting; most patients have a normal or near-normal lifespan. Mortality is not a defining feature; it relates mainly to complications of severe refractory epilepsy in a minority.
Morbidity / disability (the real burden): driven by epilepsy severity, cognitive impairment, hemiparesis/visual field loss, glaucoma-related vision loss, and cosmetic disfigurement. Jagtap et al. summarized: "Uncontrolled seizures, mental subnormality, visual handicap, and cosmetic disfigurement were the major impediments in life" (PMID:22832777).
Disease course: ~73% achieve good seizure control on medication in cohorts; ~27% are drug-resistant (PMID:22832777). Glaucoma requires lifelong monitoring; some progress to vision loss.
Prognostic factors:
Early seizure onset (< 2 years) → higher risk of intellectual disability (PMID:22832777).
Bilateral brain involvement → worse cognitive/neurologic outcome.
Extent of leptomeningeal involvement and drug-resistant epilepsy → poorer prognosis.
Prognostic biomarkers are imaging-based (atrophy/perfusion) rather than molecular at present.

12. Treatment

Management is multidisciplinary and organ-directed — neurology, ophthalmology, dermatology, and increasingly targeted molecular therapy.

Neurological / anti-seizure: - Antiepileptic drugs — first line; commonly levetiracetam and oxcarbazepine (± others), with a goal of complete seizure suppression. (CHEBI: levetiracetam CHEBI:6437; oxcarbazepine CHEBI:7824.) - Low-dose aspirin (≈3–5 mg/kg/day) — reduces frequency/severity of stroke-like episodes and seizures; one series reported stroke-like episodes falling from 1.1 → 0.3/month and median seizures 3 → 1/month after starting aspirin, and it "can be safely used in these patients" (PMID:25757597 / PMC4373084). (CHEBI: acetylsalicylic acid CHEBI:15365.) - Presymptomatic/early treatment (aspirin + AED) — hypothesis-driven strategy to delay seizure onset and protect cognition (PMC7288478). - Epilepsy surgery — for drug-resistant focal epilepsy: focal resection or hemispherectomy/hemispherotomy in appropriate unilateral cases (can achieve seizure freedom).

Targeted / emerging molecular therapy (the frontier that follows straight from §6): - Sirolimus (mTOR inhibitor) — trial of sirolimus for cognitive impairment in SWS (NCT03047980); a pilot in 10 patients (oral, ≤2 mg/day, trough 4–6 ng/mL, 6 months) found it well-tolerated with possible cognitive benefit (Sebold/Comi et al.). (CHEBI: sirolimus CHEBI:9168.) - Cannabidiol (highly purified, Epidiolex) — pilot data suggest reduced seizure frequency and improved cognitive/psychiatric/neurological outcomes (Kaplan et al., Pediatr Neurol 2021). (CHEBI: cannabidiol CHEBI:69478.) - ANGPT2/TIE2 and RAS-pathway targeting — preclinical rationale strong (Huang 2022, PMID:34670408); imatinib normalized a mutant-GNAQ vascular phenotype in a model (ResearchGate/Bichsel).

Ocular (glaucoma): - Medical: IOP-lowering drops (beta-blockers, prostaglandin analogs, carbonic anhydrase inhibitors). - Surgical: goniotomy/trabeculotomy (infantile), trabeculectomy, glaucoma drainage devices; care re: choroidal effusion risk from high episcleral venous pressure.

Cutaneous (port-wine stain): - Pulsed dye laser (PDL) — standard of care to lighten the stain (best started early). (MAXO: laser therapy — verify term.) - Topical rapamycin + PDL — Phase II RCT showed added benefit for capillary malformations in SWS (J Am Acad Dermatol 2015).

Supportive/rehabilitative: physical/occupational/speech therapy for motor and developmental deficits; headache management; psychological/psychiatric support; genetic counseling (to reassure re: negligible recurrence risk — MAXO:0000079).

Treatment algorithm (in brief): confirm dx (MRI) → start AED at/around first seizure (some advocate presymptomatic) → add low-dose aspirin → escalate to combination AEDs → epilepsy surgery if refractory → parallel lifelong glaucoma monitoring/treatment → PDL for the stain → consider sirolimus/CBD/trials for cognitive-neurologic burden.

13. Prevention

Primary prevention: not possible — you can't prevent a stochastic somatic mutation, and it isn't inherited, so there's no carrier screening or reproductive prevention to offer. Genetic counseling's role is reassurance about the very low recurrence risk.
Secondary prevention (early detection — where the real leverage is):
Screen every infant with a forehead/V1 port-wine stain for glaucoma (serial IOP) and consider early contrast MRI for leptomeningeal involvement.
Early ophthalmologic surveillance to catch glaucoma before vision loss.
Tertiary prevention (preventing complications — the core of care):
Aspirin + AEDs to reduce stroke-like episodes/seizures and protect the developing brain (PMC4373084, PMC7288478).
Trigger avoidance: aggressive management of fever/dehydration, head-injury precautions.
Ongoing IOP control to prevent optic-nerve damage.
Immunization / public-health / environmental interventions: not applicable (non-infectious, non-environmental).

14. Other Species / Natural Disease

Taxonomy: SWS as a defined clinical syndrome is essentially human-specific (NCBITaxon:9606, Homo sapiens). There is no recognized naturally-occurring animal homolog carrying the full encephalotrigeminal triad.
Orthologous genes: GNAQ and GNA11 are deeply conserved across vertebrates (mouse Gnaq — MGI; zebrafish gnaq), which is why engineered models work well (§15).
Natural disease in animals (OMIA): no established spontaneous SWS-equivalent in companion animals or wildlife; capillary/vascular malformations occur in animals but aren't cataloged as SWS.
Comparative biology: the conservation of the Gαq R183 residue and its GTPase mechanism across species is what makes cross-species modeling of the mechanism valid, even without a natural disease counterpart.
Zoonotic potential / transmission: none — not applicable.

15. Model Organisms

The mechanism is conserved enough that engineered models recapitulate key vascular biology, even though no animal spontaneously "gets SWS."

Zebrafish: mutant GNAQ transcript expression during zebrafish development was used to probe the in vivo phenotypic effects of the somatic mutation (Shirley/Pevsner lineage of work) — a fast vertebrate readout for vascular patterning.
Mouse (endothelial-specific): an endothelial-specific mouse model of Gnaq p.R183Q was recently developed to study abnormal molecular/vascular features and to enable preclinical drug and gene-therapy testing (Angiogenesis 2025, Springer; s10456-025-09986-4). These are conditional/tissue-restricted models — appropriate given the disease is mosaic and germline-wide expression is lethal.
In vitro / cellular:
HUVEC + lentiviral GNAQ R183Q — establishes a PWS-like endothelial model; mutation enhanced proliferation, migration, angiogenesis, and anti-apoptotic survival via ANGPT2/TIE2/PI3K/AKT and PKC/NF-κB/calcineurin (PMID:40917747).
Mutant-GNAQ endothelial xenograft/organoid vascular models producing enlarged vessels normalized by ANGPT2 knockdown (PMID:34670408) or imatinib.
Phenotype recapitulation: models faithfully reproduce the cellular/vascular phenotype (enlarged, malformed, hyper-angiogenic vessels; dysregulated signaling) and are excellent for drug-target validation.
Model limitations: they do not reproduce the full human triad — the leptomeningeal-specific neurological disease, seizures, and cognitive phenotype are hard to model, and mosaic timing/distribution can't be perfectly mimicked. So these are HUMAN_MODEL_MISMATCH-flavored systems: great for endothelial mechanism and therapeutics, weaker for the CNS clinical picture.
Resources: MGI (Gnaq), ZFIN (gnaq), and the published endothelial-specific mouse line; Cellosaurus for HUVEC-derived lines.

Curation notes for the dismech entry (meta)

A few things worth flagging before this becomes YAML, in the spirit of the project's anti-hallucination discipline: - Verify every ontology ID with OAK before committing — I've suggested HP/GO/CL/UBERON/CHEBI/MAXO terms, but I explicitly flagged buphthalmos (HPO) and several MAXO procedure terms as unverified. Do not paste those without runoak confirmation. Same for the exact HP IDs on hemianopia/choroidal hemangioma. - The strong, snippet-ready evidence anchors (verified exact quotes, real PMIDs) are: PMID:23656586 (GNAQ R183Q, allele fraction, definition), PMID:34670408 (ANGPT2/enlarged vessels), PMID:22832777 (seizure/glaucoma/ID frequencies and outcomes). Use those quotes verbatim. - NEC watch: GNAQ R183 (SWS/port-wine) vs GNAQ Q209 (uveal melanoma) is a real confusion risk — keep the codon explicit. Also keep GNA11 R183C distinct from GNAQ. - Module fit: this entry is a natural conformer for a vascular-malformation/angiogenesis mechanism, and the mTOR/PI3K-AKT and RAS-MAPK signaling arms overlap conceptually with existing proliferative-signaling modules — worth checking conforms_to candidates.

Sources

TL;DR for the impatient: SWS = one early somatic GNAQ R183Q (rarely GNA11 R183C) mutation that jams Gαq "on," floods PLCβ/PKC, MAPK/ERK, PI3K-AKT-mTOR, and ANGPT2/TIE2 signaling, and builds malformed capillary-venous vessels in skin (port-wine stain), brain leptomeninges (→ seizures, stroke-like episodes, cognitive decline), and eye (→ glaucoma). It's sporadic and non-inherited, diagnosed mainly by contrast MRI (+ CT tram-track calcifications later), and managed with AEDs + low-dose aspirin, glaucoma control, pulsed dye laser, and emerging sirolimus/CBD/ANGPT2-targeted approaches. The strongest citation anchors are PMID:23656586, 34670408, 22832777 — and please run the ontology IDs through OAK before you trust the ones I flagged.